Currently out of the existing stock ratings of Robert Wasserman, 155 are a BUY (88.07%), 21 are a HOLD (11.93%).

Robert Wasserman

Work Performance Price Targets & Ratings Chart

Analyst Robert Wasserman, carries an average stock price target met ratio of 47.19% that have a potential upside of 57.12% achieved within 155 days. Previously, Robert Wasserman worked at BENCHMARK.

Robert Wasserman’s has documented 324 price targets and ratings displayed on 23 stocks. The coverage was on Healthcare, Industrials, Consumer Cyclical sectors.

Most recent stock forecast was given on OABI, OmniAb at 07-Oct-2026.

Wall Street Analyst Robert Wasserman

Analyst best performing recommendations are on IPA (IMMUNOPRECISE ANTIBODIES LTD).
The best stock recommendation documented was for IPA (IMMUNOPRECISE ANTIBODIES LTD) at 4/1/2025. The price target of $3 was fulfilled within 143 days with a profit of $2.64 (733.33%) receiving and performance score of 51.28.

Average potential price target upside

AERC Aeroclean Technologies LLC DHR Danaher PRLB Proto Labs EBS Emergent Biosolutions IPA Immunoprecise Antibodies Ltd LGND Ligand Pharmaceuticals ABCL Abcellera Biologics CDXS Codexis HALO Halozyme Therapeutics RGEN Repligen TECH Bio-Techne Corp BLFS BioLife Solutions ITGR Integer Holdings Corp NEPH Nephros ANEB Anebulo Pharmaceuticals OABI OmniAb KMDA Kamada AER AerCap Holdings NV IP International Paper SGLB Sigma Labs TMO Thermo Fisher Scientific XOMA XOMA Corp CSBR Champions Oncology

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 18-Aug-2022

$7

4 years 2 months ago
(18-Aug-2022)

1/2 (50%)

$2.48 (54.87%)

49

Show more analysts

Please expand the browser size to see the chart

Which stock is Robert Wasserman most bullish on?

Potential upside of $9.58 has been obtained for RGEN (REPLIGEN)

Which stock is Robert Wasserman most reserved on?

Potential downside of -$31.84 has been obtained for HALO (HALOZYME THERAPEUTICS)
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?